pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 17·1 min read
save

Sanofi to cut 229 Massachusetts jobs a year after $9.1 billion Blueprint Medicines acquisition

Aug 17, 2026·read at STAT ↗LayoffsNegative

Sanofi announced it will lay off 229 employees in Massachusetts, according to a filing with the state's Executive Office of Labor and Workforce Development.

The workers are from Blueprint Medicines, the Cambridge biotech that Sanofi acquired for $9.1 billion in July 2025. The cuts come about a year after that purchase.

The layoffs are scheduled to occur between Oct. 9, 2026 and late June 2027 as part of Sanofi's integration and restructuring efforts.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition”

read at STAT ↗
359 words · retrieved Aug 17
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Sanofi8Blueprint Medicines Corp5ASTRAZENECA
topics
Oncology2NSCLCOphthalmologyPulmonology

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: TriGemX tacks on $94M; AnaCardio adds $71MFierce Biotech
  • Sep 8Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durabilityFierce Biotech
  • Aug 6Chutes & Ladders—BioNTech brings in Sobi CEOFierce Biotech
  • Aug 3After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA companyFierce Biotech